A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
Systems on FHIR: Driving Healthcare Innovation Through Interoperability
Interoperability is revolutionizing healthcare by enabling the seamless exchange of patient data across systems. This efficient data flow is critical…
Insights into the BZKF BORN-Project – Interview with Dr. Mandy Wahlbuhl-Becker
The Bavarian Oncological Radiology Network (BORN) is enhancing cancer diagnostics in Bavaria through standardized imaging and structured reporting. …
The Bavarian Oncological Radiology Network – Standardized Imaging for Improved Cancer Care: Interview with Dr. Mandy Wahlbuhl-Becker
The Bavarian Oncological Radiology Network (BORN) aims to support patients and medical professionals across Bavaria by standardizing imaging…